Tara A Albrecht1, Michael Boyiadzis, R K Elswick, Angela Starkweather, Margaret Rosenzweig. 1. Author Affiliations: School of Nursing (Drs Albrecht and Elswick), and Massey Cancer Center (Dr Albrecht), Virginia Commonwealth University, Richmond; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, Pennsylvania (Dr Boyiadzis); School of Nursing, University of Connecticut, Storrs (Dr Starkweather); School of Nursing, University of Pittsburgh, Pennsylvania (Dr Rosenzweig).
Abstract
BACKGROUND: Patients with a new diagnosis of acute myeloid leukemia (AML) are at risk of experiencing a high symptom burden due to the disease and its treatment, which includes a long period of hospitalization. OBJECTIVE: The aim of this pilot work was to describe the multidimensional symptoms and health-related quality of life experienced by patients with a new diagnosis of AML across induction chemotherapy. METHODS: A prospective, longitudinal descriptive study design was implemented to evaluate symptoms and health-related quality of life at the time of enrollment through 6 weeks postdiagnosis and identify who might be most at risk of experiencing high symptom burden. RESULTS: A total of 19 participants were included in this analysis. Moderate to severe levels of distress were present in 25% to 50% of participants, depending on timing in treatment. Females and those with a previous history of a psychological disorder reported higher symptom burden during treatment. CONCLUSIONS: Our findings indicate that adults with AML experience multiple distressing symptoms during the induction treatment. IMPLICATIONS FOR PRACTICE: Timely routine multidimensional assessment of symptoms in individuals undergoing induction chemotherapy treatment for AML is critical as they may be experiencing multiple concurrent symptoms. Additional research to advance symptom assessment and amelioration of distressing symptoms to improve health-related quality of life is needed in this unique population.
BACKGROUND:Patients with a new diagnosis of acute myeloid leukemia (AML) are at risk of experiencing a high symptom burden due to the disease and its treatment, which includes a long period of hospitalization. OBJECTIVE: The aim of this pilot work was to describe the multidimensional symptoms and health-related quality of life experienced by patients with a new diagnosis of AML across induction chemotherapy. METHODS: A prospective, longitudinal descriptive study design was implemented to evaluate symptoms and health-related quality of life at the time of enrollment through 6 weeks postdiagnosis and identify who might be most at risk of experiencing high symptom burden. RESULTS: A total of 19 participants were included in this analysis. Moderate to severe levels of distress were present in 25% to 50% of participants, depending on timing in treatment. Females and those with a previous history of a psychological disorder reported higher symptom burden during treatment. CONCLUSIONS: Our findings indicate that adults with AML experience multiple distressing symptoms during the induction treatment. IMPLICATIONS FOR PRACTICE: Timely routine multidimensional assessment of symptoms in individuals undergoing induction chemotherapy treatment for AML is critical as they may be experiencing multiple concurrent symptoms. Additional research to advance symptom assessment and amelioration of distressing symptoms to improve health-related quality of life is needed in this unique population.
Authors: David Cella; Sally E Jensen; Kimberly Webster; Du Hongyan; Jin-Shei Lai; Steven Rosen; Martin S Tallman; Susan Yount Journal: Value Health Date: 2012-12 Impact factor: 5.725
Authors: Patricia E Murphy; Andrea L Canada; George Fitchett; Kevin Stein; Kenneth Portier; Corinne Crammer; Amy H Peterman Journal: Psychooncology Date: 2010-03 Impact factor: 3.894
Authors: L E Carlson; M Angen; J Cullum; E Goodey; J Koopmans; L Lamont; J H MacRae; M Martin; G Pelletier; J Robinson; J S A Simpson; M Speca; L Tillotson; B D Bultz Journal: Br J Cancer Date: 2004-06-14 Impact factor: 7.640
Authors: Anmol Singh; Susan C Locke; Steven P Wolf; Tara A Albrecht; Jesse D Troy; Heather Derry; Areej El-Jawahri; Thomas W LeBlanc Journal: Support Care Cancer Date: 2021-08-17 Impact factor: 3.603
Authors: Yan Jie; Ying Wang; Jingyi Chen; Chunfeng Wang; Yingchun Lin; Rong Hu; Yong Wu Journal: Health Qual Life Outcomes Date: 2020-06-23 Impact factor: 3.186
Authors: Hermioni L Amonoo; Monica H Bodd; Matthew J Reynolds; Ashley M Nelson; Richard Newcomb; Patrick Connor Johnson; Tejaswini M Dhawale; Rachel Plotke; Lauren Heuer; Sabah Gillani; Daniel Yang; Emma C Deary; Elizabeth Daskalakis; Lauren Goldschen; Andrew Brunner; Amir T Fathi; Thomas W LeBlanc; Areej El-Jawahri Journal: Blood Adv Date: 2022-04-12